The Company at its meeting held today i.e., May 27, 2026 has entered into Share Purchase Agreement (''SPA'') for acquisition of 66.66% equity shareholding of Lifesenz Cancer Labs Private ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.9 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hemant Surgical Industries Ltd has entered into a Share Purchase Agreement to acquire 66.66% equity stake (6,666 shares) in Lifesenz Cancer Research Labs Private Limited for Rs. 19.99 crore in cash. Lifesenz, incorporated in February 2022, provides cancer research and diagnostic support services to clinicians and patients in India. The target company reported turnover of Rs. 56.75 lakh but posted a loss of Rs. 74.76 lakh with negative net worth of Rs. 221.84 lakh for FY 24-25. The acquisition is classified as a related party transaction as existing shareholders/directors of Lifesenz are also promoters of the Company. Post-acquisition, Lifesenz will become a subsidiary of Hemant Surgical. The deal is subject to conditions precedent and expected to complete by September 30, 2026.
Positive for shareholders as the acquisition expands Hemant Surgical's presence into the healthcare and cancer diagnostic segment, though the target company is currently loss-making with negative net worth, indicating execution risk.